DIACHEM S.P.A. - Resultados de la búsqueda

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vinorelbin aries 10 mg/ml konzentrat zur herstellung einer infusionslösung

apocare pharma gmbh (8082368) - vinorelbinbis[(r,r)-tartrat] - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; vinorelbinbis[(r,r)-tartrat] (26063) 13,85 milligramm

Suiza - alemán - Swissmedic (Swiss Agency for Therapeutic Products)

beriplex p/n 500 pulver und lösung zur herstellung einer injektionslösung

csl behring ag - faktor ii der blutgerinnung menschlichen, blutgerinnung faktor vii human, faktor ix gerinnung human, faktor x koagulation von menschlichem leid proteinum menschlichen c, proteinum menschlichen s - pulver und lösung zur herstellung einer injektionslösung - praeparatio cryodesiccata: proteina plasmatis humani: factor ii coagulationis humanus 400-960 u.i. et factor vii coagulationis humanus 200-500 u.i. et factor ix coagulationis humanus 400-620 u.i. et factor x coagulationis humanus 440-1200 u.i. et proteinum humanum c 300-900 u.i. et proteinum humanum s 240-760 u.i. corresp. proteina 120-280 mg, antithrombinum iii humanum, heparinum, albuminum humanum, natrii chloridum, natrii citras anhydricus, acidum hydrochloridum aut pro praeparatione. solvens: aqua ad iniectabile. - gerinnungsstörungen infolge verminderung der faktoren ii, vii, ix und x - blutprodukte

Suiza - alemán - Swissmedic (Swiss Agency for Therapeutic Products)

beriplex p/n 1000 pulver und lösung zur herstellung einer injektionslösung

csl behring ag - faktor ii der blutgerinnung menschlichen, blutgerinnung faktor vii human, faktor ix gerinnung human, faktor x koagulation von menschlichem leid proteinum menschlichen c, proteinum menschlichen s - pulver und lösung zur herstellung einer injektionslösung - praeparatio cryodesiccata: proteina plasmatis humani: factor ii coagulationis humanus 800-1920 u.i. et factor vii coagulationis humanus 400-1000 u.i. et factor ix coagulationis humanus 800-1240 u.i. et factor x coagulationis humanus 880-2400 u.i. et proteinum humanum c 600-1800 u.i. et proteinum humanum s 480-1520 u.i. corresp. proteina 240-560 mg, antithrombinum iii humanum, heparinum, albuminum humanum, natrii chloridum, natrii citras anhydricus, acidum hydrochloridum aut pro praeparatione. solvens: aqua ad iniectabile. - gerinnungsstörungen infolge verminderung der faktoren ii, vii, ix und x - blutprodukte

Unión Europea - alemán - EMA (European Medicines Agency)

tyenne

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunsuppressiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vinorelbin aurobindo 10 mg/ml konzentrat zur herstellung einer infusionslösung

puren pharma gmbh & co. kg - vinorelbinbis[(r,r)-tartrat] - konzentrat zur herstellung einer infusionslösung - vinorelbinbis[(r,r)-tartrat] 13.85mg